NPR – Share prices for the British drugmaker Indivior plunged today on the London Stock Exchange. The drop came on news that the U.S. Justice Department indicted the company on fraud and conspiracy charges.
Westport News – Six of the state’s 10 largest cities, and hundreds of others across the country, have sued OxyContin maker Purdue Pharma. So has Connecticut’s attorney general and more than 30 of his counterparts.
The Guardian – Drug company executives appearing in court in Boston this week have been accused of running “a criminal enterprise” and putting greed before patient safety as they pushed prescription narcotics during the opioids crisis, blighting the health of America.
Daily Heralds – Purdue Pharma, the controversial maker of OxyContin, and eyecare-pharmaceutical firm Ocular Therapeutix has announced a research partnership aiming to develop non-opioid pain treatments.
Stamford Advocate– The executive suing Point72 Asset Management for alleged gender discrimination and the Stamford-based firm have agreed to have her case dismissed in court and decided by a private arbitrator, according to documents filed in the past week.
My San Antonio– Purdue Pharma announced Tuesday a corporate turnaround specialist as its new board chairman and also changed its top lawyer, marking the latest in a series of organizational shifts for the embattled maker of the OxyContin opioid.
News Times– Purdue Pharma and other prescription-drug makers and distributors are being sued in five states for private health-insurance costs allegedly spiked by the opioid crisis, in what the plaintiffs’ lawyers describe as unique litigation.
PR Newswire– In lead-up to GDPR’s looming May 25, 2018 deadline, Neo4j, the market leader in connected data, is urging any company that is investing in GDPR compliance to use those investments for a long-term, strategic advantage. As part of that effort, Neo4j is offering an interactive, personalized demonstration and solution assessment, which shows organizations how to use connected data to meet GDPR compliance, and also how to turn those compliance investments into a strategic advantage.